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the preparation of this 18F-labeled RGD dimer is challenging
may considerably hamper its applications in patients.12 ThuThe development of RGD-based antagonist of avb3 integrin receptor has enhanced the interest in PET
probes to image this receptor for the early detection of cancer, to monitor the disease progression and
the response to therapy. In this work, a novel prosthetic group (N-(4-ﬂuorophenyl)pent-4-ynamide or
FPPA) for the 18F-labeling of an avb3 selective RGD-peptide was successfully prepared. [18F]FPPA was
obtained in three steps with a radiochemical yield of 44% (decay corrected). Conjugation to c(RGDfK(N3))
by the Cu(II) catalyzed Huisgen azido alkyne cycloaddition provided the [18F]FPPA-c(RGDfK) with a radio-
chemical yield of 29% (decay corrected), in an overall synthesis time of 140 min.since
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evaluated in animal models and recently the FDA has approved
ﬁrst trial with [18F]FPP(RGD)2 (IND104150).11 The speciﬁcity of this
probe against avb3 integrin has been demonstrated in vivo and on
tissue sections with competition with unlabeled peptides orchosen as therapeutic targets. The arginine–glycine–aspartate
(RGD) motif is the natural ligand sequence recognized by several
is a need for a more accessible probe to provide noninvasive
quantitative imaging of avb3 integrin expression for the evaluationintegrins, including avb3, and RGD-based soluble peptides have
been developed as antagonistic compounds (such as cilengitide)
to selectively inhibit avb3 integrin. Such peptides are currently
tested in clinical trials for their antiangiogenic and anti-tumoral
activities.4–6
Ligands for molecular imaging based on RGD peptides have al-
ready been radiolabeled with 99mTc, 111In and 123I for single photon
emission computed tomography (SPECT) imaging, while 68Ga, 64Cu
and 18F (t1/2 = 109.8 min, 97% b+, Emax = 0.64 MeV) have been
widely investigated to radiolabel RGD peptides for positron emis-
sion tomography (PET).7–10 All those radiotracers have been
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as well as for the appropriate selection of cancer patients entering
clinical trials with such therapeutic drugs.
Labeling of biomolecules with ﬂuorine-18 is usually accom-
plished through the conjugation of a targeting entity with a radio-
active prosthetic group.13 In the present study, we aimed at
labeling c(RGDfK), a cyclic peptide known to bind with high afﬁnity
and selectivity to avb3 integrin, with a radiolabeled prosth-
etic group N-(4-[18F]ﬂuorophenyl)pent-4-ynamide ([18F]3 or
[18F]FPPA).
In silico molecular docking was initially performed to check
whether the presence of the prosthetic group (FPPA) into this
structurally constrained cyclic pentapeptide might inﬂuence the
binding with the receptor. The minor contact with the protein
surface of the valine residue of cilengitide suggests that it could be
easily replaced by a lysine to provide an anchor point to generate
solvent and remains at the surface of the integrin receptor. Thus,
the modiﬁcation on the lysine residue and the incorporation of
Figure 1. Binding mode of cilengitide and FPPA-c(RGDfK). The experimental
binding mode of cilengitide (ball and stick model colored according to the atom
types) on the avb3 surface (in cornﬂower blue), compared to the calculated binding
mode of FPPA-c(RGDfK) (thick lines, with carbon atoms in magenta).
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Suggestion of a sequence modiﬁcation of the cyclic pentapeptide
allowing the addition of FPPA without compromising the binding
afﬁnity towards avb3 integrin was made by the calculation of
the binding free energy contributions made by each residue of
c(RGDfV) (cilengitide), in complex with avb3 integrin (PDB ID
1L5G).14 We chose to convert the primary amine on the side chain
of the lysine residue into an azide to facilitate the addition of the
prosthetic group to the RGD peptide by using the Huisgen’s click
reaction. This reaction was selected due to its high selectivity
and efﬁciency, the rapid formation of the triazole in presence of
copper catalyst, and the ease of puriﬁcation of the ﬁnal product.15
All those advantages are of crucial importance while we perform
labeling with trace amount of a short half-life radionuclide, such
as ﬂuorine-18. Several cyclic peptides coupled to the prosthetic
group were docked to the surface of avb3 using the EADock pro-
gram.16,17 The results demonstrated that the binding mode of the
RGDf fragment of the peptide, which is responsible for the major
part of the interaction between the ligand and the binding domain
of avb3, is conserved. The prosthetic group is oriented towardsScheme 1. Synthesis of FPPA-c(RGDfK) (5). Reagents and conditions: (a) EDC, HOBt, DCM
86%.our radiolabeled prosthetic group does not affect the binding of
the pentapeptide (Fig. 1).
FPPA (Scheme 1) has been specially designed to bear a ﬂuorine
atom and to possess a terminal alkynyl function. The ﬂuorine atom
was implemented at the 4-position of the phenyl ring of FPPA to
provide better in vivo stability. Indeed, although incorporation of
ﬂuorine-18 into prosthetic groups via substitution reactions usu-
ally proceeds better with aliphatic substrates than aromatic com-
pounds, deﬂuorination of aliphatic C–F bond is often observed
and leads to bone uptake and artifacts on the PET images.18–20
Then, a terminal alkynyl group was introduced to the prosthetic
group to allow attachment of FPPA to the peptide according to
the Huisgen’s click reaction.21 FPPA was synthesized in one step
in 91% yield starting from commercially available 4-ﬂuoroaniline
(1) and 4-pentynoic acid (2) (Scheme 1).22 The reaction was per-
formed in dichloromethane in presence of the standard coupling
agents 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
and 1-hydroxybenzotriazole (HOBt). Then, FPPA was conjugated
to c(RGDfK(N3)) by Huisgen’s 1,3-dipolar cycloaddition. The pep-
tide has been synthesized according to a reported method.23 The
reaction occurred in water/THF and was catalyzed by Cu(II) in
presence of sodium ascorbate. The latter was used as reducing
agent in slight excess (Scheme 1).24 Following the click reaction,
the salts were removed by ﬁltration and the ﬁnal product was puri-
ﬁed by HPLC. Identity of FPPA-c(RGDfK) (5) was conﬁrmed by
MALDI-TOF. Subsequently, 5 has been used as nonradioactive stan-
dard for puriﬁcation and quality control of its radiolabeled analog
[18F]-5 and to conﬁrm binding and selectivity of this RGD peptide
to avb3 integrin.
Considering that ﬂuoride is a poor nucleophile and the low acti-
vation of the 4-position on the phenyl ring of FPPA, due to the lack
of adjacent electron withdrawing groups, we decided to investigate
two radiochemical routes for the preparation of [18F]FPPA ([18F]-3)
(Scheme 2). Trimethylammonium salts were synthesized as
precursors for the 18F-ﬂuorination reaction. N-(4-(Trimethylam-
monium)phenyl)pent-4-ynamide triﬂuoromethanesulfonate (8) and
N-(4-trimethylammonium)nitrobenzene triﬂuoromethanesulfonate
(11) were obtained in two steps from 4-(dimethylamino)aniline
(6) (Scheme 2A) and 4-nitroaniline (9) (Scheme 2B), respectively., rt, overnight, 91%; (b) water/THF, CuSO4 (0.1 M), sodium ascorbate (0.3 M), rt, 1 h,
Treatment of 6 with 4-pentynoic acid gave N-(4-(dimethyl-
amino)phenyl)pent-4-ynamide (7) in 90% yield, while dimethyla-
of [18F]ﬂuoro-nitrobenzene (12) with sodium borohydride, in pres-
ence of palladium on activated carbon, gave 4-[18F]ﬂuoroaniline
Scheme 2. Synthesis of the trimethylammonium triﬂuoromethanesulfonate precursors (8) (A) and (11) (B). Reagents and conditions: (a) 2, EDC, HOBt, DCM, rt, overnight,
90%; (b) methyl triﬂuoromethanesulfonate, DCM, 2 h, 0 C, 66%; (c) (i) NaH, THF, 5 min, rt; (ii) MeI, THF, 24 h, 73%; (d) methyl triﬂuoromethanesulfonate, DCM, 0 C, 68%.
Scheme 3. Synthesis [18F]FPPA ([18F]-3). Reagents and conditions: (a) [18F]F, K222/K2CO3, CH3CN or DMSO, 60–165 C, 10–15 min, 0.4–5%; (b) 4, water/THF, CuSO4 (0.3 M),
sodium ascorbate (0.7 M), rt, 15 min, 66%; (c) [18F]F, K222/K2CO3, CH3CN, 10 min, 95 C, 69%; (d) (i) NaBH4, MeOH, Pd/C, rt, 2 min; (ii) 12 M HCl, rt, 53%; (e) 13, Et3N, DCM,
75 C, rt, 10 min, 44%.
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(10). Finally, methylation of the dimethylamino intermediates 7
and 10 with methyl triﬂuoromethanesulfonate afforded the trime-
thylammonium precursors 8 and 11 in 66% and 68% yield,
respectively.
The radiolabeled RGD peptide [18F]-5 or [18F]FPPA-c(RGDfK)
was prepared starting with the standard kryptoﬁx–K2CO3-medi-
ated nucleophilic 18F-exchange reaction with the trimethylammo-
nium triﬂate precursors 8 or 11 (Scheme 3). Introduction of the
ﬂuorine-18 using a no-carrier-added nucleophilic substitution
with K[18F]F/K222 was initially conducted with precursor 8 in ace-
tonitrile at 60 C for 10 min, but low radiochemical yield (0.4% de-
cay noncorrected) was observed. Therefore, we investigated
whether we could improve the nucleophilic incorporation of
[18F]ﬂuoride into this trimethylammonium triﬂate salt by changing
the reaction conditions (temperature, time, and solvent). We ob-
tained our best radiochemical yield of 4.9% (decay noncorrected)
with respect to initial [18F]ﬂuoride when the reaction was
performed in DMSO at 165 C for 12 min. The lack of electron with-
drawing groups on the aromatic ring that would favor the ﬂuorina-
tion at the 4-position considerably limited the efﬁcacy of this
reaction. Therefore, although this one step approach would obviate
the need of sophisticated radiochemical route to prepare [18F]FPPA,
we considered that it would not provide quantities which are prac-
tical for use as PET radiopharmaceuticals. Consequently, a three
steps radiochemical route has been established. The ﬁrst radio-
chemical step (Scheme 3B), which consisted of the 18F-ﬂuorination
of our second activated trimethylammonium precursor 11 resulted
in [18F]ﬂuoro-nitrobenzene (12), with radiochemical yield of 69%
(decay noncorrected) when the reaction mixture was heated at
95 C for 10 min in acetonitrile. Then, reduction of the nitro group([18F]-1) as an hydrochloric salt after quenching the reaction with
either 1 M HCl or 12 M HCl, with a radiochemical yields of 45% and
53% (decay corrected), respectively.25 Identity of [18F]-1 was con-
ﬁrmed by HPLC analysis by co-elution with authentic unlabeled
4-ﬂuoroaniline (Fig. 1-SD). Subsequent coupling of 4-[18F]ﬂuoroan-
iline with the 2,5-dioxopyrrolidin-1-yl pent-4-ynoate (13)26 in
dichloromethane in presence of triethylamine afforded the 18F-la-
beled prosthetic group [18F]-3 in 44% radiochemical yield (decay
corrected) within 40 min (Fig. 2-SD).
Finally, [18F]-3 was conjugated with c(RGDfK(N3)) following the
same procedure used for the preparation of the nonradioactive
conjugate (5), to obtain the 18F-labeled peptide [18F]-5 with 66%
yield (decay corrected) (Scheme 3). [18F]FPPA-c(RGDfK) was then
obtained in about 140 min with a total radiochemical yield of
29% (decay corrected). Identity of the new radiopharmaceutical
was conﬁrmed by comparing its HPLC mobility with the retention
time of the nonradioactive analogue (Fig. 3-SD).
The afﬁnity of the ﬂuorinated c-(RGDfK) was then experimen-
tally tested with an ELISA in vitro assay using recombinant solu-
ble integrins binding to their immobilized natural ligands in the
absence or presence of gradual amounts of the test peptide. Sol-
uble recombinant avb3 and a5b1 integrins were expressed in
HEK293T cells transfected with cDNA encoding for the a and b
subunits of the integrins of interest.27 All cDNAs encoded for
truncated integrins (i.e., all integrin subunits lacked their respec-
tive transmembrane and C-terminal domains) and were tagged
with either a His-tag or fused with a human IgG-Fc-fragment.
As a result expressed integrins were secreted in the culture med-
ium (‘conditioned medium’). Soluble truncated avb3 and a5b1
(a5b1 was used for speciﬁcity control) are assumed to adopt a
rod-like shape conformation associated with high afﬁnity
ligand-binding for their substrate.27 Then, IC50 values were ob-
tained by challenging binding of the integrins to the surface-
140 min total synthesis with a radiochemical yield of 29% (decay
corrected).
Figure 2. IC50 determination of the new peptide for soluble avb3 and a5b1 integrins. (A) Results of the IC50 determination test for the new peptide towards the avb3 integrin
showing a 10.6 nM value. (B) Corresponding IC50 value for the a5b1 is proximally 300 times lower than the afﬁnity for avb3. The data are the results of experiments done in
triplicate, and the standard deviations have been reported as vertical bars.
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amounts of peptide 5. A cyclic peptide c(RGDfV), which is the
equivalent structure of the cilengitide, was used as control pep-
tide to validate the method. An IC50 of 0.51 nM was obtained
for c(RGDfV) (Fig. 4-SD), which is in accordance with what has
been previously reported in the literature (IC50 ranging from
0.13 to 1.89 nM).28 For FPPA-c(RGDfK) (5), IC50 values of
10.6 nM and 3.6 lM were obtained for avb3 and a5b1, respec-
tively (Fig. 2). The difference of binding afﬁnity of 5 between
the two integrins tested clearly demonstrates the high speciﬁcity
of FPPA-c(RGDfK) for avb3 integrin. To further characterize the
properties of FPPA-c(RGDfK), we performed ﬂow-cytometry anal-
ysis on HUVEC (human umbilical vascular endothelial) cells,
which are known to highly express avb3 integrin. When bound
to integrins, high afﬁnity ligands activate the receptor.27 The
presence of activated avb3 integrin can then be detected with a
speciﬁc antibody LIBS-1 (ligand induced binding site), which
solely recognizes the activated form (ligand bound) of the b3
integrin subunit. To validate that our peptide (5) retains the same
activity of c(RGDfV) on avb3 integrin after binding, cells were
incubated with either media (negative control), 1 mM of Mn2+
or 10 lM of c(RGDfV) (both are positive controls for activation),
or with FPPA-c(RGDfK). The activation of the receptor was ob-
served in cells treated with Mn2+, c(RGDfV) and FPPA-c(RGDfK)
(Fig. 5-SD). This conﬁrms that the cyclic pentapeptide is active
towards its receptor, and the presence of the FPPA moderately af-
fects the interaction.
In summary, a novel prosthetic group N-(4-ﬂuorophenyl)pent-
4-ynamide (FPPA) for labeling of biomolecule via click reaction
has been proposed. Docking studies conﬁrmed that the presence
of FPPA on c(RGDfK) does not have a negative inﬂuence on the
interaction with the avb3 integrin receptor. Modeling predictions
were correlated with the in vitro measurements of the afﬁnity
and the activation of integrin avb3 by FPPA-c(RGDfK). [18F]FPPA
([18F]-3) was synthetized from N-(4-(trimethylammonium)
phenyl)pent-4-ynamidetriﬂuoromethanesulfonate (8) by direct
[18F]ﬂuorination in position 4, or from N-(4-trimethylammoni-
um)nitrobenzene triﬂuoromethanesulfonate (11) by a nucleophilic
aromatic ﬂuorination, a reduction of the nitro group and a conjuga-
tion with the alkynyl chain. The three steps strategy gave a better
radiochemical yield (44% decay corrected). The Cu(II)-catalyzed
azido-alkyne Huisgen’s cycloaddition has been adopted to attach
our prosthetic group with the RGD-based peptide. This strategy
yielded the ﬁnal radiopharmaceutical [18F]FPPA-c(RGDfK) inAcknowledgments
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